230 related articles for article (PubMed ID: 30668678)
1. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Tousoulis D
Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
[No Abstract] [Full Text] [Related]
2. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
[TBL] [Abstract][Full Text] [Related]
3. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
[TBL] [Abstract][Full Text] [Related]
4. AAA- a further step towards a moratorium for aspirin in the primary prevention.
Minar E
Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
[No Abstract] [Full Text] [Related]
5. Aspirin for Primary Prevention of Cardiovascular Disease.
Kheiri B; Barbarawi M; Bachuwa G; Shapiro MD
Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005846. PubMed ID: 31163982
[No Abstract] [Full Text] [Related]
6. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Godley RW; Hernandez-Vila E
Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141
[No Abstract] [Full Text] [Related]
7. Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: A meta-analysis of randomized trials.
Upadhaya S; Madala S; Baniya R; Saginala K; Khan J
Eur J Prev Cardiol; 2019 May; 26(7):746-749. PubMed ID: 30861689
[TBL] [Abstract][Full Text] [Related]
8. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
[TBL] [Abstract][Full Text] [Related]
9. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Matthys F; De Backer T; De Backer G; Stichele RV
Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
[TBL] [Abstract][Full Text] [Related]
10. Aspirin in primary prevention: USPSTF recommendations.
Aalbers J
Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
[No Abstract] [Full Text] [Related]
11. Aspirin in primary prevention of cardiovascular disease in the elderly.
Galli M; Andreotti F; D'Amario D; Vergallo R; Montone RA; Porto I; Crea F
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):326-327. PubMed ID: 31504373
[No Abstract] [Full Text] [Related]
12. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Soejima H; Morimoto T; Saito Y; Ogawa H
Thromb Haemost; 2010 Dec; 104(6):1085-8. PubMed ID: 20941462
[No Abstract] [Full Text] [Related]
13. Primary vascular prevention: The end of the road for aspirin?
Ajjan RA
Diab Vasc Dis Res; 2018 Nov; 15(6):475-476. PubMed ID: 30415566
[No Abstract] [Full Text] [Related]
14. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
[TBL] [Abstract][Full Text] [Related]
15. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
16.
Fortuni F; Crimi G; Gritti V; Mirizzi AM; Leonardi S; Ferrari GM
Eur J Prev Cardiol; 2019 Oct; 26(15):1677-1679. PubMed ID: 30744399
[No Abstract] [Full Text] [Related]
17. The role of aspirin as antiaggregant therapy in primary prevention. An update.
Jiménez-García N; de la Torre Lima J; García Alegría J
Med Clin (Barc); 2019 Oct; 153(8):326-331. PubMed ID: 31521369
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
Aung T; Haynes R; Barton J; Cox J; Murawska A; Murphy K; Lay M; Armitage J; Bowman L;
Trials; 2016 Jun; 17(1):286. PubMed ID: 27296091
[TBL] [Abstract][Full Text] [Related]
19. On the potential contribution of aspirin to healthy ageing programmes.
Morgan GP
Age Ageing; 2016 Mar; 45(2):e1-3. PubMed ID: 22101149
[No Abstract] [Full Text] [Related]
20. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
Barmanray R; Hamblin PS
Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
